Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2010

View Archived Issues

Denufosol improves lung function in patients with cystic fibrosis

Lixivaptan evaluated vs. furosemide in healthy volunteers

Tirofiban shows safety/preliminary efficacy in BAO and stroke

Merck & Co. claims new neuropeptide S receptor antagonists

New immunoprophylactic antibacterial CLDC+MPF combination presented

Aclidinium bromide shows preliminary efficacy in COPD

NeuroSearch discloses new GABA(A) receptor modulators

Lilly claims new hedgehog signaling inhibitors

New FABP inhibitors presented

MDX-1097 is evaluated in phase I trial in multiple myeloma

Phase I trial data presented on GSK-923295 in solid tumors

GlaxoSmithKline discloses highlights of first quarter 2010

PolyMedix completes phase Ib trial of PMX-60056 for reversal of heparin action

Ascenta and sanofi-aventis sign license agreement in oncology

Scancell and ImmuneRegen BioSciences form strategic alliance

H4 receptor antagonist UR-63325 yields favorable first-in-human data

AstraZeneca submits Axanum MAA in E.U.

Bausch and Lomb acquires Zirgan ophthalmic gel from Sirion

TauRx and Bayer Schering enter into AD collaboration

Preliminary phase III data reported on oral insulin spray

Janssen expands licensing agreement for tapentadol

FDA grants orphan drug status to GVAX CML vaccine

CombinatoRx receives milestone payment for Prednisporin

Grifols to acquire Talecris Biotherapeutics

TK therapy R&D project receives grant from Regione Lombardia

FDA accepts DM-1796 NDA for postherpetic neuralgia

Phase III trial of plitidepsin initiated in multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...